Published on
January 3, 2023
- 12:30 GMT
Evaxion receives approval from FDA to proceed with the clinical Phase 2b study for EVX-01
COPENHAGEN, Denmark, Jan. 03, 2023 (GLOBE NEWSWIRE) -- Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion” or the “Company”), a clinical-stage biotechnology company specializing in the development of AI-driven immunotherapies, today announced that the U.S. Food …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Technology
...
